Loading company…
ID 400243036 · FY 2019–2024 · 6 years
კომპანიის ძირითად საქმიანობას წარმოადგენს ფარმაცევტული პროდუქციით საბითუმო ვაჭრობა.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross Margin | 60.0% | 57.9% | 59.2% | 63.8% | 51.9% | 51.7% |
| EBITDA Margin | 47.1% | 44.1% | 37.5% | 32.5% | 47.8% | 41.6% |
| EBITDAR | 1,380 | 4,751 | 3,127 | 1,285 | 4,265 | 4,231 |
| EBITDAR Margin | 47.1% | 44.1% | 37.5% | 32.5% | 47.8% | 41.8% |
| EBIT Margin | 47.1% | 44.1% | 37.5% | 32.5% | 47.8% | 41.6% |
| Net Profit Margin | 47.5% | 51.5% | 27.9% | 5.2% | 48.4% | 40.9% |
| Operating Expense % of Sales | 12.9% | 13.8% | 21.8% | 31.3% | 4.1% | 10.2% |
| Returns | ||||||
| Return on Assets (ROA) | 79.9% | 71.2% | 21.6% | 2.0% | 29.1% | 23.2% |
| Return on Equity (ROE) | 89.8% | 80.9% | 25.5% | 2.3% | 32.1% | 23.6% |
| ROIC [EBIT / Invested Capital] | 93.7% | 69.7% | 35.2% | 14.4% | 33.0% | 24.3% |
| Leverage & liquidity | ||||||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 88.9% | 88.0% | 84.6% | 89.0% | 90.7% | 98.3% |
| Net Debt | -76 | -40 | -254 | -291 | -525 | -192 |
| Cash & Equivalents | 76 | 40 | 254 | 291 | 525 | 192 |
| Total Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Efficiency & working capital | ||||||
| Inventory Turnover | N/A | N/A | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover | 10.24x | 1.88x | 2.13x | 0.89x | 1.03x | 1.37x |
| Days Sales Outstanding (DSO) | 35.6 | 194.1 | 171.1 | 411.5 | 355.4 | 266.2 |
| Payables Turnover | 6.58x | 5.28x | 2.05x | 1.26x | 3.13x | 45.04x |
| Days Payable Outstanding (DPO) | 55.5 | 69.1 | 178.0 | 289.9 | 116.7 | 8.1 |
| Cash Conversion Cycle | -19.8 days | 125.0 days | -6.9 days | 121.6 days | 238.7 days | 258.1 days |
| Asset Turnover | 1.68x | 1.38x | 0.77x | 0.38x | 0.60x | 0.57x |
| Cash flow & dividends | ||||||
| Operating Cash Flow | 124 | 162 | 334 | 340 | 375 | -223 |
| Free Cash Flow (OCF − Capex proxy) | 124 | 162 | 334 | 340 | 375 | -223 |
| Cash Conversion (OCF / EBITDA) | 9.0% | 3.4% | 10.7% | 26.5% | 8.8% | -5.3% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.